<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979732</url>
  </required_header>
  <id_info>
    <org_study_id>GSE 2009-050</org_study_id>
    <nct_id>NCT00979732</nct_id>
  </id_info>
  <brief_title>The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension</brief_title>
  <acronym>GSE</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effect of Grape Seed Extract Delivered in a Beverage on Blood Pressure in Individuals With Pre-hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Nutrition Research Center, Illinois Institute of Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Polyphenolics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Nutrition Research Center, Illinois Institute of Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study, the investigators are interested in learning how extracts from grape&#xD;
      seeds can help those individuals with high blood pressure. The investigators also hope to&#xD;
      learn how grape seed extract effects your blood and cell functions.&#xD;
&#xD;
      The grape seed extract the investigators will use in the study will be provided either in a&#xD;
      beverage or a capsule form and is currently available on the market. This study is also using&#xD;
      a placebo; therefore the treatment subjects receive may or may not contain the grape seed&#xD;
      extract.&#xD;
&#xD;
      The purpose of this study is to determine if the grape seed extract (GSE) will lower blood&#xD;
      pressure in people with slightly high blood pressure (Pre-Hypertension).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated blood pressure, or hypertension, is a major risk factor for heart disease and&#xD;
      stroke. Systolic and diastolic blood pressures meeting criteria for &quot;pre-hypertension&quot; double&#xD;
      the absolute risk of stroke and ischemic heart disease over an extended age range from the&#xD;
      4th to the 8th decade of life. Lifestyle, particularly the diet, is critical in the&#xD;
      prevention and management of hypertension. Polyphenolic compounds from various plant foods&#xD;
      can promote blood pressure regulation and vascular health through protection of the&#xD;
      endothelium from oxidant and or inflammatory stress and or stimulation of smooth muscle&#xD;
      relaxation.&#xD;
&#xD;
      We will use a purified grape seed extract (GSE) in the proposed trial. This extract has been&#xD;
      granted Generally Recognized as Safe (GRAS) status by Food and drug administration (GRAS&#xD;
      Notice # GRN 000125, dated 08/18/2003, FDA, USA). Furthermore, GSE for use in the present&#xD;
      trial has been used in previous human clinical trails and shown potent vasodilator properties&#xD;
      in vitro and blood pressure lowering in metabolic syndrome patients. The proposed trial aims&#xD;
      to verify the blood pressure lowering effect of GSE in an 'at risk' population for&#xD;
      hypertension and to explore the extent to which other pathways of chronic disease may be&#xD;
      modulated by GSE consumption.&#xD;
&#xD;
      Given this, the objectives of this study are as follows:&#xD;
&#xD;
        1. The primary objective of the proposed study is to demonstrate the effectiveness of GSE&#xD;
           to lower blood pressure in pre-hypertensive individuals.&#xD;
&#xD;
        2. Secondary objectives will investigate the role of GSE to improve inflammatory- and&#xD;
           oxidative stress- status, as well as its effect on endothelium function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2009</start_date>
  <completion_date type="Actual">October 15, 2014</completion_date>
  <primary_completion_date type="Actual">October 15, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>6 weeks</time_frame>
    <description>BP was monitored using ambulatory BP monitors (Ambulo2400; Tiba Medical, Inc.) that were programmed to take BP measurements automatically at 1-h intervals for a period of 24 h. BP measurements were scheduled at week 0 and 6 of the intervention (for efficacy assessment). Day-time BP and night-time BP were divided based on the subject's sleeping hours and hours awake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Insulin Level Over 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>After 10-12 h of overnight fasting, fasting blood samples were collected at week 0 (baseline) and week 3 and 6 of the intervention. plasma insulin were evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>GSE beverage active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>grape seed extract beverage 150 mg/BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSE beverage placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>grape seed extract placebo beverage 150 mg/BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>grape seed extract</intervention_name>
    <description>grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
    <arm_group_label>GSE beverage active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>grape seed extract placebo</intervention_name>
    <description>grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
    <arm_group_label>GSE beverage placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male and female&#xD;
&#xD;
          -  pre-hypertensive&#xD;
&#xD;
               -  systolic blood pressure (mmHg) 120 - 139 or&#xD;
&#xD;
               -  diastolic blood pressure (mmHg) 80 -89&#xD;
&#xD;
          -  no clinical evidence of cardiovascular, respiratory, renal, gastrointestinal or&#xD;
             hepatic disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant and or lactating&#xD;
&#xD;
          -  taking over the counter antioxidant supplements&#xD;
&#xD;
          -  taking prescription medications that may interfere with study procedures or endpoints&#xD;
&#xD;
          -  unusual dietary habits&#xD;
&#xD;
          -  actively trying to lose or gain weight&#xD;
&#xD;
          -  addicted to drugs and/or alcohol&#xD;
&#xD;
          -  medically documented psychiatric or neurological disturbances&#xD;
&#xD;
          -  smoker (past smoker may be allowed if cessation is &gt; 2 years)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britt Burton-Freeman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Nutrition Research Center, Illinois Institute of Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Indika Edirisinghe, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Nutrition Research Center, Illinois Institute of Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Nutrition Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Edirisinghe I, Burton-Freeman B, Tissa Kappagoda C. Mechanism of the endothelium-dependent relaxation evoked by a grape seed extract. Clin Sci (Lond). 2008 Feb;114(4):331-7.</citation>
    <PMID>17927567</PMID>
  </reference>
  <reference>
    <citation>Brahmesh S, Edirisinghe I, Randolph J, Steinberg F and Kappagoda T. Effect of a polyphenoics extracts of grape seeds (GSE) on blood pressure in patients with metabolic syndrome (MetS). FASEBJ. 2006;20:A305.</citation>
  </reference>
  <reference>
    <citation>Sivaprakasapillai B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism. 2009 Dec;58(12):1743-6. doi: 10.1016/j.metabol.2009.05.030. Epub 2009 Jul 15.</citation>
    <PMID>19608210</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <results_first_submitted>April 23, 2018</results_first_submitted>
  <results_first_submitted_qc>January 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2021</results_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high blood pressure</keyword>
  <keyword>dietary supplements</keyword>
  <keyword>nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Grape Seed Extract</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was performed at the Clinical Nutrition Research Center at the Illinois Institute of Technology (Chicago, IL, USA) from 2010 to 2014.</recruitment_details>
      <pre_assignment_details>Eligible subjects started with a 2-week run-in period drinking the Placebo beverage twice per day. After the 2-week run-in period, subjects were randomised to one of the two groups (Placebo or GSE beverage), equally allocated to each treatment (1:1 randomisation ratio).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSE Beverage Active</title>
          <description>grape seed extract beverage 150 mg/BID&#xD;
grape seed extract: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
        </group>
        <group group_id="P2">
          <title>GSE Beverage Placebo</title>
          <description>grape seed extract placebo beverage 150 mg/BID&#xD;
grape seed extract placebo: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data were collected at the screening</population>
      <group_list>
        <group group_id="B1">
          <title>GSE Beverage Active</title>
          <description>grape seed extract beverage 150 mg/BID&#xD;
grape seed extract: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
        </group>
        <group group_id="B2">
          <title>GSE Beverage Placebo</title>
          <description>grape seed extract placebo beverage 150 mg/BID&#xD;
grape seed extract placebo: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="10"/>
                    <measurement group_id="B2" value="42" spread="10"/>
                    <measurement group_id="B3" value="43" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure</title>
        <description>BP was monitored using ambulatory BP monitors (Ambulo2400; Tiba Medical, Inc.) that were programmed to take BP measurements automatically at 1-h intervals for a period of 24 h. BP measurements were scheduled at week 0 and 6 of the intervention (for efficacy assessment). Day-time BP and night-time BP were divided based on the subject's sleeping hours and hours awake.</description>
        <time_frame>6 weeks</time_frame>
        <population>All completers</population>
        <group_list>
          <group group_id="O1">
            <title>GSE Beverage Active</title>
            <description>grape seed extract beverage 150 mg/BID&#xD;
grape seed extract: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
          </group>
          <group group_id="O2">
            <title>GSE Beverage Placebo</title>
            <description>grape seed extract placebo beverage 150 mg/BID&#xD;
grape seed extract placebo: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>BP was monitored using ambulatory BP monitors (Ambulo2400; Tiba Medical, Inc.) that were programmed to take BP measurements automatically at 1-h intervals for a period of 24 h. BP measurements were scheduled at week 0 and 6 of the intervention (for efficacy assessment). Day-time BP and night-time BP were divided based on the subject's sleeping hours and hours awake.</description>
          <population>All completers</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" spread="2.3"/>
                    <measurement group_id="O2" value="127" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Insulin Level Over 6 Weeks</title>
        <description>After 10-12 h of overnight fasting, fasting blood samples were collected at week 0 (baseline) and week 3 and 6 of the intervention. plasma insulin were evaluated.</description>
        <time_frame>6 weeks</time_frame>
        <population>All completer</population>
        <group_list>
          <group group_id="O1">
            <title>GSE Beverage Active</title>
            <description>grape seed extract beverage 150 mg/BID&#xD;
grape seed extract: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
          </group>
          <group group_id="O2">
            <title>GSE Beverage Placebo</title>
            <description>grape seed extract placebo beverage 150 mg/BID&#xD;
grape seed extract placebo: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Insulin Level Over 6 Weeks</title>
          <description>After 10-12 h of overnight fasting, fasting blood samples were collected at week 0 (baseline) and week 3 and 6 of the intervention. plasma insulin were evaluated.</description>
          <population>All completer</population>
          <units>ÂµIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="1.5"/>
                    <measurement group_id="O2" value="20.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSE Beverage Active</title>
          <description>grape seed extract beverage 150 mg/BID&#xD;
grape seed extract: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
        </group>
        <group group_id="E2">
          <title>GSE Beverage Placebo</title>
          <description>grape seed extract placebo beverage 150 mg/BID&#xD;
grape seed extract placebo: grape seed extract 150 mg twice a day (BID) in beverage or capsule form</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was not sufficiently powered to detect significant differences on the secondary end points. We observed large inter-individual variability in plasma phenolic concentrations, requiring a greater sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Britt Burton-Freeman</name_or_title>
      <organization>Illinois Institute of Techology</organization>
      <phone>708-341-0178</phone>
      <email>bburton@iit.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

